May 17, 2020

BP Healthcare to invest Rs 100 mln to set up dental care network

Leading healthcare player
largest dental care network
firs
Admin
2 min
BP Healthcare to invest Rs 100 mln to set up dental care network
Leading healthcare player, BP Healthcare Group will be investing Rs 100 million over the next three years to establish the largest dental care network...

Leading healthcare player, BP Healthcare Group will be investing Rs 100 million over the next three years to establish the largest dental care network, the news reports said.

BP Healthcare will be adding up to 50 outlets by the end of the period which will complement the group’s overall thrust on wellness and health, the company said in a press statement. It also said, “The first dental clinic will open in the second week of September as the BP Specialist Centre in Glenmarie, Shah Alam to be followed by another three more at its specialist centres in Cheras, Klang and Ipoh in November.”  

BP Healthcare Deputy Chairman, Chevy Beh said, “Within the next three years, we will have 50 dental care clinics throughout the country. Each will cost RM2 million and the bulk of the investment will be spent on buying the best and latest equipments from abroad.”

The new company BP Dental Sdn Bhd has been established under the group to lead this new business as it moves up the value chain.

It aims to enhance its range and delivery of healthcare services to the customers. BP Healthcare was expected to add another 15 to 20 clinics next year and the remaining in 2014.

These clinics would be located within the existing BP outlets and dental checks will be included in BP Healthcare’s popular comprehensive Head2Toe health screening programme. Mr. Beh also said, “The establishment of BP Dental would bring about a new challenge for BP Healthcare to create greater awareness among Malaysians on the importance of oral health and adopt a preventive mindset.”

BP Healthcare Group is a diversified healthcare provider and Southeast Asia’s largest medical diagnostic chain with more than 90 outlets in Malaysia and a joint venture in Indonesia with well-known Ciputra Group.
 

Share article

Jul 28, 2021

5 mins with... Johannes Bhakdi, Quantgene

COVID19
Genomics
AI
biotechnology
3 min
5 mins with... Johannes Bhakdi, Quantgene
Johannes Bhakdi, CEO of Quantgene, tells us about their approach to identifying new COVID-19 variants

Quantgene is a US biotech company that uses AI and the cloud to do genomic testing. It was founded in 2015 to focus on cancer - integrating advanced genomics and molecular diagnostics systems with the cloud and AI systems. 

CEO Johannes Bhakdi tells us Quantgene is the first COVID-19 testing company to fully integrate variant identification - we find out more. 

Given the new Delta and Lambda variants, is the coronavirus mutating at a faster rate than most viruses?
 
The reason SARS-COV2 is mutating on a perceived higher rate is not that the individual viruses mutate at a higher rate, but that the base population infected with the virus is vastly higher. The absolute rate of global mutations is a direct function of how many people have the virus at any given point in time. Since this is a global pandemic, and tens of millions have been infected, we see more mutations. 

That makes it more unpredictable, because any single mutation that has an evolutionary advantage - like the Delta variant - can then take over and spread even faster.  

What is the usual process for testing and analysing viral mutations? 

The most effective tool for analysing mutations is Whole Viral Genome sequencing. It allows you to read out the entire genome of the virus. Once the wet-lab sequencing is complete, we use this information to map it against what is called a "reference genome", meaning the classic SARS-COV2 genome. This allows us to then see any differences between the investigated sample and the baseline genome of SARS COV2. 

We then use these differences to map them against a database of known mutations, like the Delta variant. That way we can see if we are dealing with any known variant, and if we have a new variant at our hands, as well as determine what this new variant does to the spike protein and how likely it is to be a problem with antigens and vaccines, based on the changed protein structure. This last step is not easy and not clear-cut, and there is some speculation into the determination of how problematic the mutated proteins are. 

 What does Quantgene do differently?  

At Quantgene, we are focusing on solving problems for our clients - may it be employers, movie productions or governments. That means we ensure that our client gets the COVID protection they need in the fastest possible time frame and at the highest precision possible - mostly at or below market prices. 

We are bringing together technologies like RT-PCR testing and mutation profiling/sequencing, as well as advanced bioinformatics and computational resources to ensure high-quality results are being delivered seamlessly. 

We are also adding important components such as real-time cloud software and medical services to it. Simply put, we turn the COVID problem into a one-click seamless solution that works better than others, so companies and government clients don't have to deal with laboratories, medical or software providers who point fingers at each other and fail to deliver in time and with high precision. COVID is too dangerous and important to risk falling short.     

Share article